Pontus Nobréus appointed as Business Development Director

Biovica announces the appointment of Pontus Nobréus as Business Development Director, effective end of May 2018. Mr Nobréus has over 20 years’ experience working within the global sales, commercial and business development roles.  Most recently, he was Global Sales Manager at Euro Diagnostica.

Pontus Nobréus will initially be based in Sweden. Pontus will be responsible for global business development, which includes sales, commercialization and customer strategy. He will be part of the management team at Biovica.

"I'm looking forward to start working with the Biovica team and making DiviTum commercially available. It's inspiring to work with a product with so much potential, both from a human and commercial perspective!" says Pontus Nobréus, new Business Development Director Biovica.

“Pontus Nobréus is an important addition to Biovica. His personality and extensive experience of successfully taking diagnostic products to the market will be important as Biovica enters the phase of commercializing the product.” says Anders Rylander, CEO Biovica.

More information:

Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
E-mail: anders.rylander@biovica.com

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labelled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more: www.biovica.com

Tags:

About Us

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Subscribe

Media

Media

Documents & Links

Quotes

I'm looking forward to start working with the Biovica team and making DiviTum commercially available. It's inspiring to work with a product with so much potential, both from a human and commercial perspective!
Pontus Nobreus, Business Development Director Biovica
Pontus Nobréus is an important addition to Biovica. His personality and extensive experience of successfully taking diagnostic products to the market will be important as Biovica enters the phase of commercializing the product.
Anders Rylander, CEO Biovica